Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 71

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 71
---
 of this proxy statement/prospectus entitled “Questions And Answers About The Proposals — How will the level of redemptions by NorthView’s stockholders affect the ownership of non -redeeming NorthView’s stockholders in New Profusa upon the closing of the Business Combination?” Reasons for the Approval of the Business Combination After careful consideration, NorthView’s Board recommends that NorthView Holders vote “FOR” each proposal being submitted to a vote of the NorthView Holders at the special meeting. In considering its recommendation to its stockholders, the board has identified certain factors in making the determination, including but not limited to: •Profusa is in the health care sector with near term revenue potential. Its biosensor technology and developed applications have been validated and its Lumee O2 product is approved in EU while seeking FDA approval in US; •Profusa’s biosensor technology and AI monitoring is a true platform with meaningful revenue growth prospects; •Profusa’s proven and experienced management team led by Ben Hwang, PhD and co -founder; and •The Marshall and Stevens fairness opinion (See “ The Business Combination Proposal— Opinion of Marshall & Stevens” for additional information regarding the preparation of the fairness opinion). For a description of NorthView’s reasons for the approval of the Business Combination and the recommendation of NorthView’s Board, see the section entitled “ The Business Combination — The NorthView Board’s Reasons for the Approval of the Business Combination”. Redemption Rights Pursuant to NorthView’s Amended and Restated Certificate of Incorporation, we are providing our public stockholders with the opportunity to redeem all or a portion of their public shares of NorthView Common Stock for cash upon consummation of the Business Combination. The per share redemption price will be equal to the aggregate amount then on deposit in the Trust Account that holds the proceeds of our IPO, including interest (net of taxes payable), divided by the number of then outstanding public shares. For illustrative purposes, based on funds in the trust account of approximately $1.9 million on March21, 2025, the estimated per share redemption price would have been approximately $12.21. Any such redemptions will increase the dilutive impact on non -redeemingshareholders, as fewer shares will remain outstanding. If you properly exercise your redemption rights, your shares of NorthView Common Stock will cease to be outstanding immediately prior to the Business Combination and will only represent the right to receive a pro rata share of the aggregate amount on deposit in the Trust Account. You will no